Completion of share buy-back program

Company Announcement

COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024

On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. 

The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares. 

The following transactions were executed under the program from March 11 to March 15, 2024:

	No. of shares	Average price (DKK)	Total value (DKK)
Accumulated through last announcement	177,000		351,215,900
March 11, 2024	3,000	2108.03	6,324,090
March 12, 2024	3,000	2131.04	6,393,120
March 13, 2024	3,000	2141.95	6,425,850
March 14, 2024	2,000	2112.14	4,224,280
March 15, 2024	2,000	2070.53	4,141,060
Total	13,000		27,508,400
Accumulated under the program	190,000		378,724,300

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 865,972 shares as treasury shares, corresponding to 1.31% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 14, 2024.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines.